Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;63(11):1103-1110.
doi: 10.1007/s00120-024-02455-8. Epub 2024 Oct 10.

[Testosterone replacement therapy and possible side effects]

[Article in German]
Michael Zitzmann  1 , Martin C Michel  2 , Herbert Sperling  3
Affiliations
Review

[Testosterone replacement therapy and possible side effects]

[Article in German]
Michael Zitzmann et al. Urologie. 2024 Nov.

Abstract
in English, German

The substitution of testosterone is basic andrological treatment. Beside the "when and how," knowledge of possible side effects is mandatory. Therefore, we highlight the effects of testosterone replacement therapy on bones, cardiac function, sexuality, gynacomatia, fertility, and contraception, but also areas of concern regarding prostate carcinoma and testosterone replacement therapy.

Der Testosteronersatz ist andrologische Basistherapie – neben wann und wie ist das Wissen um Nebenwirkungen essentiell. Vorgestellt werden Aus- und Nebenwirkungen der Testosteronsubstitution mit den Schwerpunkten: Knochenstoffwechsel, Herz, psychosexuelle Interferenzen, Gynäkomastie, Fertilität und Kontrazeption sowie das Spannungsfeld Prostatakarzinom und Testerosteronersatz.

Keywords: Bone metabolism; Cardiovascular risk; Prostate carcinoma; Sexual function; Testosterone.

PubMed Disclaimer

References

Literatur

    1. Lenk VS (2005) Diagnostik des „aging male“ – was ist sinnvoll? Urologe 44(10):1167–1172
    1. Ludwig G (2000) PADAM aus urologischer Sicht. Urologe A 39(5):407–410
    1. Corona G et al (2022) Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. J Endocrinol Invest 45:911 - DOI - PubMed
    1. Snyder PJ et al (2018) Lessons From the Testosterone Trials. Endocr Rev 39:369 - DOI - PubMed - PMC
    1. Ng Tang Fui M et al (2021) Effect of Testosterone Treatment on Bone Microarchitecture and Bone Mineral Density in Men: A 2-Year RCT. J Clin Endocrinol Metab 106:e3143 - DOI - PubMed
Weiterführende Literatur
    1. Bhasin S, Travison TG, Pencina KM, O’Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, Tangen CM, Buhr KA, Thompson IM (2023) Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open 6:12 - DOI
    1. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM (2017) Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med 177(4):471–479 - DOI - PubMed - PMC
    1. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS (2018) Lessons From the Testosterone Trials. Endocr Rev 39(3):369–386 - DOI - PubMed - PMC
    1. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A (2021) Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2‑year, phase 3b trial. Lancet Diabetes Endocrinol 9(1):32–45 - DOI - PubMed
    1. Pencina KM, Travison TG, Artz AS, Lincoff AM, Nissen SE, Flevaris P, Chan A, Li X, Diegel SA, Wannemuehler K, Bhasin S (2023) Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open 6:10 - DOI

MeSH terms

LinkOut - more resources